Similar trends were observed in the 4636 tumors, where the combination treatment induced substantial inhibition of tumor growth, confirming that dual targeting of GIPC-1 and chemotherapy enhances therapeutic outcomes. The gene discussed is GIPC1; the disease is neoplasm.